In an ever-evolving biopharma landscape, the quest for real-world evidence (RWE) shines as a guiding light, offering valuable insights into patient outcomes and treatment effectiveness. But what happens when resource constraints cast shadows on this path of discovery? Precision Value & Health’s Ross Maclean sits down with Christophe Segalini and Alexander Büsser to tackle this question head-on and explore how small biotechs are navigating these challenges with innovative strategies and leveraging technology to redefine RWE generation.

Read the Article Here!